[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiotherapy-adjuvant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiotherapy-adjuvant":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,71,106,137,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100641646","molecular-subtype-guided-postoperative-radiotherapy-for-phyllodes-tumor-of-the-breast-a-randomized-controlled-trial-100641646",false,"NCT07657169","Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast: A Randomized Controlled Trial","Efficacy and Safety of Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast: A Prospective, Open-Label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Female patients aged ≥18 years and ≤75 years.\n2. Histologically confirmed breast phyllodes tumor (PT) by the central laboratory, with molecular classification as MN1 or MN2 subtype via transcriptome sequencing or IHC;\n3. Primary or ipsilateral local recurrence following R0 resection (negative margins) before enrollment;\n4. Pathologically confirmed borderline or malignant PT;\n5. No evidence of distant metastasis (M0);\n6. ECOG performance status 0-1;\n7. Signed informed consent before treatment;\n8. Expected randomization and study entry within 8-12 weeks (no later than 16 weeks) after surgery.\n\nExclusion Criteria:\n\n1. Previous radiation to the same-side breast or chest;\n2. women, or those of childbearing potential refusing effective contraception; Pregnancy, lactation, or refusal of contraception by fertile subjects;\n3. Grade III-IV bone marrow suppression: WBC≤1.9\\*109\u002FL，ANC≤0.9\\*109\u002FL，PLT≤49\\*109\u002FL，AST, ALT≥2\\*ULN;\n4. Significant diarrhea, severe active infection, uncontrolled systemic disease, interstitial lung disease, active connective tissue disease, or LVEF \\\u003C 50%;\n5. Significant diarrhea, severe active infection, uncontrolled systemic disease, interstitial lung disease, active connective tissue disease, or LVEF \\\u003C 50%;\n6. Prior or planned systemic anti-tumor therapy (chemotherapy, targeted therapy, immunotherapy, or investigational agents) during the study;\n7. Participation in other clinical trials that precludes study inclusion;\n8. Any other condition that, in the opinion of the investigator, renders the patient unsuitable for the trial.","FEMALE","18 Years","75 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"NA","Phyllodes tumor (PT) of the breast is a rare fibroepithelial neoplasm, and the role of postoperative radiotherapy (PORT) remains controversial. Our team has previously established a molecular subtyping system for PT, classifying patients into four subtypes. Among them, the malignant novel 1\u002F2 (MN1\u002FMN2) subtypes exhibit extremely high risk of local recurrence, and retrospective data suggest that PORT may significantly improve local control in these subtypes. This study aims to evaluate the efficacy and safety of molecular subtype-guided postoperative radiotherapy (PORT) in patients with MN-subtype phyllodes tumor of the breast. This prospective, multicenter, open-label, randomized controlled trial plans to enroll 160 patients with molecularly confirmed MN1 or MN2 subtype who have undergone R0 resection. Patients will be randomized in a 1:1 ratio to either the PORT group or the observation-only group, with stratification by negative margin width (\\\u003C1 cm vs. ≥1 cm) and molecular subtype (MN1 vs. MN2). The primary endpoint is 2-year local recurrence-free survival (LRFS). Secondary endpoints include distant metastasis-free survival (DMFS), disease-free survival (DFS), overall survival (OS), and the incidence of acute and late radiotherapy-related toxicities. By using an innovative molecular subtyping system to precisely select the target population, this study seeks to assess the benefit and safety of PORT in MN-subtype phyllodes tumors. The results are expected to provide the highest level of evidence for this specific subgroup, advance treatment strategies toward \"molecular subtype-guided precision radiotherapy,\" improve patient outcomes, and inform future clinical guidelines.",[27,28,29,30],"Radiotherapy, Adjuvant","Phyllodes Breast Tumor","Prognosis","Molecular Typing","NOT_YET_RECRUITING","2026-06-15",{"date":34,"type":35},"2026-06-18","ACTUAL",{"date":37,"type":21},"2026-06-01",{"date":39,"type":21},"2030-12-31",{"name":41,"class":42},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","OTHER",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100632487","mr-guided-adaptive-stereotactic-radiotherapy-for-endometrial-cancer-100632487","NCT07514325","MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer","MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer (MASTEC)","MASTEC","Inclusion criteria\n\nIn order to be eligible to participate in this study, a participant must meet all of the following criteria:\n\n* Women aged 18 years or older with histologically proven carcinoma of the endometrium, treated with curative hysterectomy with or without bilateral salpingo-oophorectomy. All histologies may be included (endometrioid, clear cell carcinoma, de-\u002Fundifferentiated carcinoma, carcinosarcoma, other non-endometrioid)\n* Candidate for adjuvant EBRT as decided by multidisciplinary tumour board, amongst others:\n\n  * FIGO IB grade 3 endometrioid carcinoma\n  * FIGO stage II endometrioid carcinoma\n  * FIGO stage IIIA-C1 endometrioid carcinoma\n  * FIGO IB-II clear cell carcinoma\n  * FIGO IA-III carcinosarcioma\n* Patients receiving adjuvant systemic therapy are eligible when these therapies will not be administered concurrently\n* Patients receiving vaginal vault brachytherapy are eligible\n* Capable of giving informed consent\n\nExclusion criteria\n\nA potential participant who meets any of the following criteria will be excluded from participation in this study:\n\n* Contra-indications for MRI according to the guidelines of the local department of Radiology, inability to lay on a treatment table for 45-60 minutes or severe claustrofobia\n* Presence of para-aortic lymph node metastases (FIGO stage IIIC2)\n* Prior pelvic radiotherapy\n* WHO performance score \\> 2",{"count":53,"type":21},61,[24],"Rationale: External beam radiotherapy (EBRT) is an important cornerstone in treatment to reduce locoregional relapse in high(-intermediate) risk endometrial cancer (EC) patients. MR-guided adaptive radiotherapy (MGART) allows for more accurate delivery of radiation beams to the patients by visualizing and correcting for interfraction motion, with subsequent reduction of safety margins around the radiotherapy plan. Objective: The MASTEC study will investigate the safety of hypofractionated MR-guided adaptive radiotherapy in five fractions for elective pelvic nodal and vaginal vault irradiation in endometrial cancer.\n\nStudy design: Phase II multicentre intervention study Study population: Patients with endometrial cancer that receive adjuvant EBRT to the pelvic nodal areas and vaginal vault (with or without vaginal brachytherapy).\n\nIntervention (if applicable): MR-guided adaptive radiotherapy (MGART) with reduced PTV margins, including 5 times 6Gy to the vaginal vault and pelvic nodal areas, 2 times a week .\n\nMain study parameters\u002Fendpoints: The primary endpoint is acute gastrointestinal and genitourinary toxicity, scored by the Common Terminology Criteria Adverse Events version 6.0. Secondary endpoints are late gastrointestinal and genitourinary toxicity, quality of life and disease free survival; disease-specific survival; overall survival and metastasis-free survival.",[57,27],"Endometrial Cancer",[59,60,61],"endometrial cancer","MR-guided radiotherapy","hypofractionation","2026-03-31",{"date":64,"type":35},"2026-04-07",{"date":66,"type":21},"2026-05-01",{"date":68,"type":21},"2033-03-01",{"name":70,"class":42},"Radboud University Medical Center",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":79,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100577486","phase-3-flap-sparing-in-postoperative-radiotherapy-of-oral-cavity-cancers-100577486","NCT06798922","Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers","Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers: a De-escalation Randomized Phase III Trial","OPTIFLAP","Inclusion Criteria:\n\n* Patient aged 18 years or older\n* Performance Status 0-2\n* Patient with oral cavity cancer (soft tissue or soft tissue-bone flap), treated by reconstructive surgery with a flap. Oropharynx cancer whose flap extends significantly into the oral cavity may be included in the study\n* Quality of resection with margins \\> 1 mm\n* Patient candidate to post-operative radiotherapy (Intensity-Modulated Radiation Therapy (IMRT) or proton therapy)\n* Concomitant chemotherapy is allowed (stratification parameter)\n* Patient must have signed a written informed consent form prior to any trial specific procedures\n* Patient affiliated to the social security system\n\nExclusion Criteria:\n\n* Local flap (small size limiting IMRT modulation potential)\n* History of radiotherapy of head and neck area\n* Metastatic disease\n* History of other malignancy within the previous 3 years (except for appropriately treated in-situ cervix carcinoma and non-melanoma skin carcinoma)\n* Simultaneous participation in another clinical study may compromise the conduct of this study.\n* Pregnant or lactating women\n* Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol\n* Patient deprived of freedom or under guardianship","ALL",{"count":81,"type":21},348,[83],"PHASE3","Patients with oral cavity cancer treated by reconstructive surgery with a flap.\n\nPatients will be treated in the study for :\n\n* Experimental arm: Post-operative radiotherapy with flap sparing\n* Control arm: Standard post-operative radiotherapy without flap sparing (current practice) Radiotherapy by IMRT using photons or proton therapy (IMPT)",[86,87,27,88],"Oral Cavity Carcinoma","Flap","Reconstruction Surgery",[90,91,92,93,94],"protontherapy","flap","oral cavity carnicoma","radiotherapy","IMRT","RECRUITING","2026-03-02",{"date":98,"type":35},"2026-03-03",{"date":100,"type":35},"2025-03-01",{"date":102,"type":21},"2034-03-01",{"name":104,"class":42},"Centre Francois Baclesse",25,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":79,"minAge":17,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":123,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100607289","phase-3-adjuvant-radiotherapy-of-sintilimab-versus-tace-for-hcc-100607289","NCT07186621","Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC","Adjuvant Radiotherapy Combined With Sintilimab Versus Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma With Narrow Margins and High-Risk Features Following Resection: A Multi-center Phase III Randomized Controlled Trial","Inclusion Criteria:\n\n1. R0 resection of hepatocellular carcinoma (HCC) with a surgical margin \\\u003C1 cm (determined by postoperative pathology, surgical records, and imaging).\n2. Within 4 months after curative resection.\n3. High-Risk Recurrence Factors (at least one required in addition to narrow margin): (1) Microvascular invasion (MVI) positive, tumor thrombus, or satellite nodules (2) Preoperative AFP \\>400 ng\u002FmL (3) Tumor \\>5 cm with incomplete capsule\n4. ≥18 and ≤80 years old.\n5. ECOG score 0-1.\n6. Child-Pugh Class: A5, A6, or B7.\n7. Postoperative Contrast-enhanced MRI of the liver must be performed to exclude intrahepatic residual lesions.\n8. HBV DNA and HCV RNA status do not affect eligibility, but if HBV DNA positive and\u002For HCV RNA positive: ALT must be \\\u003C1.5× upper limit of normal (ULN). Antiviral therapy must be initiated.\n9. Liver Function Tests (LFTs): ALT ≤2.5× ULN (if HBV\u002FHCV positive, ALT ≤1.5× ULN). If ALT ≤1.5× ULN, AST ≤6× ULN (excluding AST elevation due to myocardial infarction). If ALT 1.5-2.5× ULN, AST ≤2.5× ULN.\n10. No significant ECG abnormalities and no severe cardiac dysfunction.\n11. Serum creatinine (CRE) and BUN ≤2.5× ULN.\n12. Hb≥80g\u002FL，ANC≥1.0×109 \u002FL，PLT≥40×109 \u002FL.\n13. Written informed consent obtained.\n\nExclusion Criteria:\n\n1. Vp3 or Vp4 portal vein tumor thrombus (PVTT) or Vv2\u002FVv3 inferior vena cava (IVC) tumor thrombus on preoperative imaging.\n2. Previous anti-HCC therapies, including but not limited to: targeted therapy (e.g., tyrosine kinase inhibitors), immune checkpoint inhibitors (e.g., PD-1\u002FPD-L1 inhibitors) or systemic chemotherapy\n3. Distant metastasis before randomization.\n4. Moderate to severe ascites unresponsive to medical management.\n5. History of other malignancies, except: carcinoma in situ，early-stage papillary thyroid cancer or basal cell carcinoma of the skin\n6. Previous radiotherapy involving the abdomen.\n7. Significant cardiac, renal, or other major organ dysfunction.\n8. Active Autoimmune Disease or Psychiatric Disorders.\n9. HIV Infection.\n10. Pregnant or breastfeeding women.\n11. Currently enrolled in another interventional clinical trial.","80 Years",{"count":115,"type":21},286,[83],"This study is an open-label, randomized controlled, multicenter, phase III clinical trial",[119,27,120,121,122],"Hepatocellular Carcinoma (HCC)","Immune Checkpoint Inhibitor","TACE","Narrow Margin",[124,93,125,126,121],"hepatocellular carcinoma","narrow margin","sintilimab","2025-09-16",{"date":129,"type":35},"2025-09-22",{"date":131,"type":35},"2025-07-10",{"date":133,"type":21},"2028-11-30",{"name":135,"class":42},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",1,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":152,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":136},"100601877","clinical-research-on-moderately-hypofractionated-adaptive-postoperative-radiotherapy-for-high-risk-endometrial-cancer-100601877","NCT07116213","Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer","Inclusion Criteria:\n\n* Age : 18-70 years old.\n* Performance Status :\n\nECOG score 0-2.\n\n* Expected to comply with oART (Online Adaptive Radiotherapy) workflow.\n* Initial Surgical Treatment :\n\nTotal hysterectomy and bilateral salpingo-oophorectomy ± Pelvic and\u002For para-aortic lymph node dissection\u002Fsampling or sentinel lymph node biopsy.\n\n* Pathological Staging \\& Histology (per FIGO 2009):\n\nStage I :\n\nGrade 3 endometrioid adenocarcinoma with superficial myometrial invasion and extensive LVSI (Lymphovascular Space Invasion).\n\nGrade 2 endometrioid adenocarcinoma with deep myometrial invasion and extensive LVSI.\n\nGrade 3 endometrioid adenocarcinoma with deep myometrial invasion. Stage II-IIIC1 : Endometrioid carcinoma. Stage I-IIIC1 : Serous carcinoma or clear cell carcinoma.\n\n* Informed Consent :\n* Patients and families fully understand the study protocol.\n* Voluntarily participate and sign informed consent forms before enrollment\n\nExclusion Criteria:\n\n* Prior Radiotherapy : History of abdominal or pelvic irradiation.\n* Treatment Interval :\n\nWithout adjuvant chemotherapy: \\>12 weeks between surgery and radiotherapy initiation.\n\nWith adjuvant chemotherapy: \\>6 months between surgery and radiotherapy initiation.\n\n* Malignancy History : Prior diagnosis of other malignancies.\n* Pregnancy\u002FLactation : Pregnant or breastfeeding women.\n* Active Infection : Fever or uncontrolled active infection.\n* Inflammatory Bowel Disease (IBD) : History of IBD (regardless of activity status).\n* Comorbidities : Severe conditions affecting trial compliance, including: Unstable cardiac disease requiring treatment, renal impairment, chronic hepatitis, poorly controlled diabetes, psychiatric disorders","70 Years",{"count":145,"type":21},20,[24],"1. Study Type: Single-center, single-arm, prospective study.\n2. Sample Size: 20 patients with high-risk endometrial cancer were enrolled.\n3. Treatment Procedure:\n\n   The existing clinical oART (Online Adaptive Radiotherapy) workflow protocol for malignant tumors used in our department was applied.\n\n   Procedures included simulation, target volume delineation, radiotherapy planning, and treatment delivery.\n\n   External beam radiation therapy (EBRT) was delivered using moderate hypofractionation.\n\n   If indicated, brachytherapy was performed after the completion of EBRT. When combined with chemotherapy, radiotherapy could be administered during chemotherapy intervals or after completion of chemotherapy.\n4. Study Endpoints:\n\nPrimary Endpoint: Incidence of acute toxicity. Secondary Endpoints: 3-year failure-free survival (FFS) rate, incidence of chronic toxicity, quality of life (QoL), treatment costs, etc.",[57,149,27,150,151],"Hypofractionated Dose","Side Effects","Survival , Tumor",[59,153,154],"Hypofractionated dose","Radiotherapy","2025-08-04",{"date":157,"type":35},"2025-08-11",{"date":159,"type":35},"2025-06-30",{"date":161,"type":21},"2030-12-30",{"name":163,"class":42},"Xiaorong Hou",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":79,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":174,"studyType":175,"phases":4,"briefSummary":176,"conditions":177,"keywords":182,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":136},"100579637","safety-and-efficacy-of-impt-or-imrt-for-breast-cancer-100579637","NCT06826885","Safety and Efficacy of IMPT or IMRT for Breast Cancer","The Safety and Efficacy of IMPT or IMRT for Breast Cancer: A Prospective Observational Study","SEPPT-BC","Inclusion Criteria\n\n* Aged ≥18 years old\n* Karnofsky Performance Status (KPS) score ≥70\n* Histologically confirmed breast cancer with indications for preoperative radiotherapy, postoperative radiotherapy, or definitive radiotherapy as determined by the treating physician.\n* ER (estrogen-receptor), PR (progesterone-receptor), HER2 (human epidermal growth factor receptor 2), and Ki67 testing must be performed on the primary breast tumor.\n* Women of child-bearing potential must agree to use adequate contraception starting 1 month before study treatment and throughout the duration of study participation.\n* Ability to understand and willingness to participate in the research and sign the informed consent form.\n\nExclusion Criteria\n\n* Pregnant or lactating women.\n* Severe non-neoplastic medical comorbidities that may interfere with treatment or study participation.\n* Active collagen vascular disease or other autoimmune disorders that could significantly increase the risk of radiation toxicity.\n* Patients with contraindications to undergoing IMPT or IMRT, such as severe claustrophobia that cannot be managed or inability to remain immobilized during treatment.",{"count":173,"type":21},500,"5 Years","OBSERVATIONAL","The purpose of this trial is to compare the toxicities and efficacy of intensity-modulated proton therapy (IMPT) and intensity-modulated radiation therapy (IMRT) for breast cancer patients indicated for radiotherapy including preoperative radiotherapy, postoperative radiotherapy, or definitive radiotherapy. IMPT or IMRT will be administered to the whole breast, chest wall, and\u002For regional lymph nodes. A boost dose will be delivered in patients with high-risk area, at the discretion of the radiation oncologist. Eligible breast cancer patients will be followed for at least 5 years to assess acute and late radiation induced toxicities, loco-regional recurrence, overall survival, distant metastasis, and quality of life.",[178,179,180,181,27],"Breast Cancer","Proton Therapy","Intensity Modulated Radiation Therapy","Efficacy and Safety",[183,184,185,94,186,187,188],"postoperative radiotherapy","preoperative radiotherapy","IMPT","breast cancer","efficacy","toxicity","2025-02-13",{"date":191,"type":35},"2025-02-14",{"date":193,"type":35},"2024-12-01",{"date":195,"type":21},"2029-11-30",{"name":197,"class":42},"Ruijin Hospital"]